Peak Bio Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Peak Bio's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 24.3% per year.
Belangrijke informatie
-2.6%
Groei van de winst
81.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | -24.3% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -1,307.1% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Peak Bio geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -5 | 6 | 0 |
| 31 Mar 24 | 0 | -8 | 7 | 0 |
| 31 Dec 23 | 0 | -13 | 8 | 0 |
| 30 Sep 23 | 1 | -19 | 12 | 0 |
| 30 Jun 23 | 0 | -21 | 11 | 0 |
| 31 Mar 23 | 1 | -18 | 11 | 0 |
| 31 Dec 22 | 1 | -13 | 9 | 0 |
| 30 Sep 22 | 0 | -8 | 4 | 0 |
| 30 Jun 22 | 0 | -8 | 4 | 0 |
| 31 Mar 22 | 1 | -8 | 3 | 0 |
| 31 Dec 21 | 1 | -8 | 2 | 0 |
Kwaliteitswinsten: PKBO is currently unprofitable.
Groeiende winstmarge: PKBO is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: PKBO is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.
Versnelling van de groei: Unable to compare PKBO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: PKBO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: PKBO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.